These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34834526)

  • 1. Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs.
    Michaud V; Bikmetov R; Smith MK; Dow P; Darakjian LI; Deodhar M; Cicali B; Bain KT; Turgeon J
    J Pers Med; 2021 Nov; 11(11):. PubMed ID: 34834526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
    Reizine N; Danahey K; Schierer E; Liu P; Middlestadt M; Ludwig J; Truong TM; van Wijk XMR; Yeo KJ; Malec M; Ratain MJ; O'Donnell PH
    Oncologist; 2021 Nov; 26(11):e2042-e2052. PubMed ID: 34423496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug-gene interaction risk among opioid users in the U.S. Department of Veterans Affairs.
    Chanfreau-Coffinier C; Tuteja S; Hull LE; MacDonald S; Efimova O; Bates J; Voora D; Oslin DW; DuVall SL; Lynch JA
    Pain; 2022 Dec; 163(12):2390-2397. PubMed ID: 35319502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of CYP2D6 Inhibitors with CYP2D6 Opioids: Association with Emergency Department Visits for Pain.
    Nahid NA; McDonough CW; Wei YJ; Cicali EJ; Gong Y; Fillingim RB; Johnson JA
    Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38797987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of CYP2D6 drug-drug interactions on hydrocodone effectiveness.
    Monte AA; Heard KJ; Campbell J; Hamamura D; Weinshilboum RM; Vasiliou V
    Acad Emerg Med; 2014 Aug; 21(8):879-85. PubMed ID: 25156930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Opioids Prescribed for Patients at Risk for Opioid Misuse Before and After Publication of the Centers for Disease Control and Prevention's Opioid Prescribing Guidelines.
    Scherrer JF; Tucker J; Salas J; Zhang Z; Grucza R
    JAMA Netw Open; 2020 Dec; 3(12):e2027481. PubMed ID: 33263762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
    Susce MT; Murray-Carmichael E; de Leon J
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How frequently are contraindicated or warned against combinations of drugs prescribed to patients receiving long-term opioid therapy for chronic pain?
    Richarz U; Jacobs A; Spina E
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):453-62. PubMed ID: 22081534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6-inhibiting drugs and the increased risk of fall-related injuries due to newly initiated opioid treatment--a Swedish, register-based case-crossover study.
    Möller J; Laflamme L; Söderberg Löfdal K
    Basic Clin Pharmacol Toxicol; 2015 Feb; 116(2):134-9. PubMed ID: 24975450
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Dagostino C; Allegri M; Napolioni V; D'Agnelli S; Bignami E; Mutti A; van Schaik RH
    Pharmgenomics Pers Med; 2018; 11():179-191. PubMed ID: 30425549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.
    Ballester P; Muriel J; Peiró AM
    Expert Opin Drug Metab Toxicol; 2022 Apr; 18(4):261-275. PubMed ID: 35649041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
    Ruano G; Kost JA
    Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.
    Zahari Z; Ismail R
    Drug Metab Pharmacokinet; 2014; 29(1):29-43. PubMed ID: 23759977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrocodone, Oxycodone, and Morphine Metabolism and Drug-Drug Interactions.
    Coates S; Lazarus P
    J Pharmacol Exp Ther; 2023 Nov; 387(2):150-169. PubMed ID: 37679047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of cytochrome P450 2D6 inhibitors on a high-dose tramadol taper for medically supervised opioid withdrawal: a retrospective chart review.
    Stump T; Cather J; Moore PS
    J Addict Dis; 2021; 39(1):81-87. PubMed ID: 32921297
    [No Abstract]   [Full Text] [Related]  

  • 17. Opioid pharmacokinetic drug-drug interactions.
    Overholser BR; Foster DR
    Am J Manag Care; 2011 Sep; 17 Suppl 11():S276-87. PubMed ID: 21999760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Tramadol for Pain Management in Patients Receiving Strong Cytochrome P450 2D6 Inhibitors.
    Frost DA; Soric MM; Kaiser R; Neugebauer RE
    Pharmacotherapy; 2019 Jun; 39(6):724-729. PubMed ID: 31038218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.
    Ellis JJ; Sadosky AB; Ten Eyck LL; Mudumby P; Cappelleri JC; Ndehi L; Suehs BT; Parsons B
    BMC Health Serv Res; 2015 Apr; 15():159. PubMed ID: 25889173
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    St Sauver JL; Olson JE; Roger VL; Nicholson WT; Black JL; Takahashi PY; Caraballo PJ; Bell EJ; Jacobson DJ; Larson NB; Bielinski SJ
    Pharmgenomics Pers Med; 2017; 10():217-227. PubMed ID: 28769582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.